Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum [0.03%]
左半结直肠癌一线西妥昔单抗和帕尼单抗联合双药化疗的比较：日本大肠癌学会多中心真实世界观察性研究
Ryosuke Kawagoe,Toshikazu Moriwaki,Kentaro Yamazaki et al.
Ryosuke Kawagoe et al.
Background: For patients with left-sided metastatic colorectal cancer (mCRC), the recommended first-line treatment is anti-epidermal growth factor receptor (anti-EGFR) antibodies, such as cetuximab or panitumumab, plus do...
Evaluation of neoadjuvant chemotherapy followed by radical hysterectomy in cervical cancer: a single-center study [0.03%]
宫颈癌新辅助化疗后行根治性子宫切除术的疗效分析：单中心报告
Akitoshi Yamamura,Masayo Ukita,Hiromi Takemura et al.
Akitoshi Yamamura et al.
Background: The efficacy of neoadjuvant chemotherapy (NACT) before radical hysterectomy (RH) in cervical cancer remains unclear. We evaluated stage-specific outcomes of NACT-RH at a high-volume center. ...
Prognostic value of creatinine-cystatin C ratio in individuals with cancer: a meta-analysis [0.03%]
癌性肾损害标志物血清胱抑素C与肌酐的比值的预后价值：系统评价和 Meta 分析
Wei Zhou,Xinyu Wang,Tingting Wang et al.
Wei Zhou et al.
Background: The prognostic value of the creatinine-cystatin C ratio (CCR) in individuals with cancer has been investigated in numerous studies, but the findings vary. To accurately identify the prognostic value of CCR in ...
Long-term follow-up of neoadjuvant chemotherapy in resectable human papillomavirus-associated oropharyngeal cancer [0.03%]
可切除的人乳头瘤病毒感染相关的口咽癌新辅助化疗的长期随访研究
Ryo Kawaura,Tomoya Yokota,Kunihiro Fushiki et al.
Ryo Kawaura et al.
Background: De-escalation strategies have gained increasing attention for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). We previously introduced an approach using upfront neoadjuvant...
The global burden of alcohol-attributable cancers from 1990 to 2021: assessment and projection based on the global burden of disease study 2021 [0.03%]
2021年全球疾病负担研究视角下的1990至2021年全球酒精归因癌症疾病负担的评估与预测
Zhiqi Hu,Zheng Gong,Ze Zhang et al.
Zhiqi Hu et al.
Background: Alcohol consumption is a well-established risk factor for multiple cancer types, yet its contribution to the global cancer burden remains insufficiently quantified. This study systematically assesses the globa...
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer [0.03%]
日本PMDA关于抗癌药物审批及【使用注意事项】修订的监管更新；派姆单抗用于头颈部癌症，图卡替尼用于乳腺癌，曲马替尼用于卵巢癌
Noriomi Matsumura
Noriomi Matsumura
Multidisciplinary prospective study of standardized pelvic lymph-node dissection focusing on the dorsal obturator nerve region [0.03%]
一项多学科前瞻性研究：以股深神经为重点的标准化盆腔淋巴结清扫术
Tomokazu Sazuka,Yuji Habu,Keisuke Matsusaka et al.
Tomokazu Sazuka et al.
Background: Pelvic lymph-node dissection is performed across multiple surgical specialties. However, inconsistent terminology and unclear anatomical boundaries hinder standardization. This study established a multidiscipl...
Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702) [0.03%]
由冷变热胰腺癌迎来希望之光：p53表达溶瘤型腺病毒（OBP-702）疗法前景可期
Shinji Kuroda,Hiroshi Tazawa,Masashi Hashimoto et al.
Shinji Kuroda et al.
Pancreatic cancer remains one of the most lethal malignancies, with limited therapeutic options and poor responsiveness to immune checkpoint inhibitors (ICIs). This resistance is largely attributed to its profoundly immunosuppressive and de...
The efficacy and safety of docetaxel with cisplatin compared with other chemotherapies in definitive chemoradiotherapy for head and neck squamous cell carcinoma: a real-world study [0.03%]
关于定义性化学放射治疗头颈鳞状细胞癌患者使用多西他赛与顺铂相比其他化疗药物的疗效和安全性的真实世界研究
Takumi Kumai,Yuto Izumiya,Misaki Hayashi et al.
Takumi Kumai et al.
Background: Regarding concurrent chemoradiotherapy (CCRT), the combination of docetaxel and cisplatin (DP regimen) is a promising option for treating head and neck squamous cell carcinoma (HNSCC) with a relatively low dos...